| Summary: | 碩士 === 臺北醫學大學 === 醫學研究所 === 93 === Coronary atherosclerotic heart disease is the most common cause of cardiovascular disability in Taiwan, and postangioplasty restenosis is a complicating factor in the treatment of atherosclerotic heart disease. The ability to alter the pathophysiology of coronary artery disease or control the proliferative events that lead to restenosis would be a major advancement in the treatment of the disease.
Our study use PMC (2, 2, 5, 7, 8-pentamethyl-6-hydroxychromane), a potent alpha-tocopherol analogue, inhibits rat vascular smooth cell proliferation through PKC-alpha in MTT assay study.We found PMC also can inhibit effectively rat vascular smooth cell into S phase. PKC-alpha intimately involved in the proliferation, migration, growth, and survival of VSMC, and these factors have been shown to be important in the development of atherosclerotic lesions as well as restenosis after vascular injury.
We use PMA, as a PKC-alpha activator, to stimulate PKC-alpha in the smooth muscle cell of blood vessels; translocation phenomenon of PKC-alpha from cytoplasm to cell membrane was obvious. Then PMC can effectively inhibit translocation phenomenon of PKC-alpha from cytoplasm to cell membrane after PMA stimulation. And the immune fluorescence study showed same result as above. So, we found PMC can inhibits rat vascular smooth muscle cell proliferation through PKC-alpha. This study can provide new therapeutic strategy for atherosclerosis and post angioplastic restenosis.
|
|---|
